Literature DB >> 3520950

An eight-year study of HLA typing proficiency in Eurotransplant.

G M Schreuder, G F Hendriks, J D'Amaro, G G Persijn.   

Abstract

The main purpose of Eurotransplant, an international organ exchange organisation, is to maximize the survival time of transplanted organs through tissue typing and matching. Regular proficiency testings are necessary to assess the reproducibility and the reliability of the HLA typings performed by the individual typing centres. Two different protocols have been used: 1) since 1978, 35 samples of blood and donor spleen were used for cell exchanges (CE) and typed by all participating laboratories; 2) since 1977 samples of donor spleen have been shipped to the reference laboratory in Leiden for retyping (RD) resulting in over 2600 comparable HLA typings. The discrepancy rates of the HLA-A, B, C and DR specificities were analysed over the years. A large number of discrepancies was due to false negative assignments which led to assumed homozygosity at one or more HLA-loci. The recognition of HLA-DR has improved dramatically but with much variation per DR specificity. The concordancy rates for HLA-AB + DR have improved from 40% in 1981 to 91% for CE and 80% for RD typings in 1984. The reproducibility of DR typings in individual laboratories also has improved greatly but there is still considerable variation between the different laboratories.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3520950     DOI: 10.1111/j.1399-0039.1986.tb01512.x

Source DB:  PubMed          Journal:  Tissue Antigens        ISSN: 0001-2815


  2 in total

1.  Treatment with cyclosporin and risks of graft rejection in male kidney and heart transplant recipients with non-O blood.

Authors:  G F Hendriks; E P van Steenberge; G M Schreuder; G J Wenting; B Mochtar; E Bos; M L Simoons; A H Balk; K Laird-Meeter; C E Essed
Journal:  BMJ       Date:  1988-10-08

2.  [HLA B27 seems to promote graft failure following penetrating keratoplasties for herpetic corneal scars].

Authors:  D Böhringer; R Sundmacher; T Reinhard
Journal:  Ophthalmologe       Date:  2007-08       Impact factor: 1.059

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.